Targets › VEGFR3
2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Dec 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. (UniProt, P35916)
Open in Phaseline: the race on VEGFR3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fei Gao | Donafenib Multi-kinase inhibitor targeting FGFR and VEGFR | FGFR1, VEGFR1, VEGFR2, VEGFR3 | Phase 2 | Hepatocellular Carcinoma with PVTT | Dec 2026 |
| Karie Runcie | Zanzalintinib (XL092) Multi-targeted receptor tyrosine kinase inhibitor targeting VEGF receptors | VEGFR1, VEGFR2, VEGFR3 | Phase 2 | Advanced Renal Cell Carcinoma | Dec 2027 |
Advanced Renal Cell Carcinoma (1) Hepatocellular Carcinoma with PVTT (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.